Updated Jul 16, 2026 · Last SEC filing 2026-07-06
Keros Therapeutics, Inc. (KROS) has filed 12 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-06. 4 Form 8-K material event filings were reported by KROS in the last 90 days. 4 Form 144 notices of proposed sale were filed for KROS stock. InsiderAlpha tracks every KROS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001664710 |
| Form 4 filings (90d) | 12 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 4 |
| Latest Form 4 filing | 2026-07-06 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Prener Anne | Insider | A — Grant or award | 13.8K | $0.00 | — | SEC | |
| BIENAIME JEAN JACQUES | Insider | P — Open-market purchase | 1.0K | $10.19 | $10K | SEC | |
| Newton Charles W. | Insider | S — Open-market sale | 550 | $10.04 | $6K | SEC | |
| Seth Alpna | Insider | S — Open-market sale | 2.6K | $10.72 | $28K | SEC | |
| Knowles Julius | Insider | S — Open-market sale | 2.6K | $10.73 | $28K | SEC | |
| Farzan Nima | Insider | S — Open-market sale | 2.6K | $10.73 | $28K | SEC | |
| BIENAIME JEAN JACQUES | Insider | A — Grant or award | 7.1K | $0.00 | — | SEC | |
| Knowles Julius | Insider | A — Grant or award | 7.1K | $0.00 | — | SEC | |
| GRAY MARY ANN | Insider | A — Grant or award | 7.1K | $0.00 | — | SEC | |
| Farzan Nima | Insider | A — Grant or award | 7.1K | $0.00 | — | SEC | |
| BIENAIME JEAN JACQUES | Insider | P — Open-market purchase | 1.0K | $10.58 | $11K | SEC | |
| BIENAIME JEAN JACQUES | Insider | P — Open-market purchase | 1.0K | $11.70 | $12K | SEC | |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER | M — Option exercise | 55.0K | $0.30 | $16K | SEC | |
| BIENAIME JEAN JACQUES | Insider | P — Open-market purchase [10b5-1] | 2.0K | $11.21 | $22K | SEC | |
| Newton Charles W. | Insider | A — Grant or award | 13.2K | $0.00 | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Keros Therapeutics, Inc. (KROS). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| BIENAIME JEAN JACQUES | 5 | $32K |
| Knowles Julius | 3 | $28K |
| Farzan Nima | 3 | $28K |
| Prener Anne | 2 | — |
| GRAY MARY ANN | 2 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in KROS insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live KROS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.